Developing into a Global Category Pharma Built on Glycoscience
First written in FY2016. 17 of 20 entries say "Restated". Latest entry: 2026-08-05.
No other company in this theme has enough history to compare yet.
- 2026-08-05RestatedEarnings
「To contribute to healthy and fulfilling lives for people worldwide, the Group aims to create innovative pharmaceuticals and other products by specializing in glycoscience, its area of expertise.」
The company reaffirmed its basic policy of specializing in carbohydrate science and creating innovative pharmaceuticals and other products. - FY2026-H1RestatedAnnual report
「To contribute to healthy and fulfilling lives for people worldwide, the Group aims to create innovative pharmaceuticals and other products by specializing in glycoscience, its area of expertise.」
The basic policy of specializing in glycoscience and creating innovative pharmaceuticals and other products remains in place. - FY2025RestatedAnnual report
「Our basic policy is to contribute to healthy and fulfilling lives for people worldwide by continuously creating and providing patients with innovative pharmaceuticals and other products that draw on our knowledge of glycoscience, guided by the management motto “Originality, Fairness, Dreams and Passion.”」
The basic policy of creating innovative pharmaceuticals and other products based on glycoscience and contributing to global health remains in place. - FY2024-Q3RestatedAnnual report
「To contribute to healthy and fulfilling lives for people worldwide, the Group aims to create innovative pharmaceuticals and other products by specializing in glycoscience, its area of expertise.」
The basic policy of specializing in glycoscience and creating innovative pharmaceuticals and other products remains in place. - FY2024-Q1RestatedAnnual report
「To contribute to healthy and fulfilling lives for people worldwide, the Group aims to create innovative pharmaceuticals and other products by specializing in glycoscience, its area of expertise.」
The basic policy of specializing in glycoscience and creating innovative pharmaceuticals and other products remains in place. - FY2022-Q2RestatedAnnual report
「To contribute to healthy and fulfilling lives for people worldwide, the Group aims to create innovative pharmaceuticals and other products by specializing in glycoscience, its area of expertise.」
The basic policy of specializing in glycoscience and creating innovative pharmaceuticals and other products remains in place. - FY2022-Q1RestatedAnnual report
「To contribute to healthy and fulfilling lives for people worldwide, the Group aims to create innovative pharmaceuticals and other products by specializing in glycoscience, its area of expertise.」
There has been no material change to the basic policy of specializing in glycoscience and creating innovative pharmaceuticals and other products. - FY2021RestatedAnnual report
「Our basic policy is to contribute to healthy and fulfilling lives for people worldwide by continuously creating and providing patients with innovative pharmaceuticals and other products that draw on our knowledge of glycoscience, guided by the management motto “Originality, Fairness, Dreams and Passion.”」
The basic policy of creating innovative pharmaceuticals and other products based on glycoscience and contributing to global health remains in place. - FY2021-Q3RestatedAnnual report
「To contribute to healthy and fulfilling lives for people worldwide, the Group aims to create innovative pharmaceuticals and other products by specializing in glycoscience, its area of expertise.」
The basic policy of specializing in glycoscience and creating innovative pharmaceuticals and other products remains in place. - FY2020-Q3RestatedAnnual report
「“A company with global value through innovative drug discovery.” We aim to become a company with genuine value by applying our knowledge in glycoscience to proprietary technologies, creating innovative new drugs that are truly needed, and contributing to healthy and fulfilling lives worldwide by making those drugs more broadly available globally.」
The vision of creating innovative new drugs based on glycoscience and proprietary technologies and providing them globally remains in place. - FY2020-Q2ReframedAnnual report
「“A company with global value through innovative drug discovery.” We aim to become a company with genuine value by applying our knowledge in glycoscience to proprietary technologies, creating innovative new drugs that are truly needed, and contributing to healthy and fulfilling lives worldwide by making those drugs more broadly available globally.」
The wording and position in the plan have been revised from the previous 10-Year Vision of becoming a Global Category Pharma to a medium-term vision centered on innovative drug discovery and creating value worldwide. - FY2019ReframedAnnual report
「Against this backdrop, in March 2009 we formulated the Biochemistry Industry 10-Year Vision and have pursued development as a “Global Category Pharma.”」
While reviewing the 10-Year Vision as the focus of the past decade, the company is carrying forward its policy of placing glycoscience at the center of drug discovery in the next medium-term management plan. - FY2019-Q3RestatedAnnual report
「• We will develop the capabilities to launch new drugs, including medical devices, at a consistent pace and to develop a market capable of becoming a core earnings pillar approximately once every 3 years. • By focusing research and development on glycoscience and establishing international competitiveness, we will sustain steady growth as a Global Category Pharma.」
The 10-Year Vision centered on launching new drugs, developing markets, and concentrating research and development on glycoscience remains in place. - FY2019-Q2RestatedAnnual report
「• We will develop the capabilities to launch new drugs, including medical devices, at a consistent pace and to develop a market capable of becoming a core earnings pillar approximately once every 3 years. • By focusing research and development on glycoscience and establishing international competitiveness, we will sustain steady growth as a Global Category Pharma.」
The 10-Year Vision of focusing research and development on glycoscience while continuing to launch new drugs and develop new markets is reiterated. - FY2018-Q3RestatedAnnual report
「We will develop the capabilities to launch new drugs, including medical devices, at a consistent pace and to develop a market capable of becoming a core earnings pillar approximately once every 3 years.」
The long-term goals under the 10-Year Vision, including launching new drugs and developing a market that can become a core earnings pillar approximately once every 3 years, are reiterated. - FY2018-Q1RestatedAnnual report
「In March 2009, we formulated the Biochemistry Industry 10-Year Vision and have aimed to develop as a “Global Category Pharma.”」
The policy of pursuing a Global Category Pharma centered on glycoscience, based on the 10-Year Vision, is reiterated. - FY2017RestatedAnnual report
「We will develop the capabilities to launch new drugs, including medical devices, at a consistent pace and to develop a market capable of becoming a core earnings pillar approximately once every 3 years.」
The Biochemistry Industry 10-Year Vision and the Global Category Pharma policy of focusing research and development on glycoscience remain in place. - FY2017-Q3RestatedAnnual report
「We will develop the capabilities to launch new drugs, including medical devices, at a consistent pace and to develop a market capable of becoming a core earnings pillar approximately once every 3 years.」
The 10-Year Vision, the policy of pursuing a Global Category Pharma position, and the long-term goals of launching new drugs and developing markets are reiterated. - FY2017-Q1RestatedAnnual report
「In March 2009, we formulated the Biochemistry Industry 10-Year Vision and have aimed to develop as a “Global Category Pharma.”」
The policy of pursuing the 10-Year Vision and becoming a Global Category Pharma remains in place. - FY2016First statedAnnual report
「In March 2009, we formulated the Biochemistry Industry 10-Year Vision and have aimed to develop as a “Global Category Pharma.”」
The long-term goals are to launch new drugs consistently, develop a market capable of becoming a core earnings pillar approximately once every 3 years, and establish international competitiveness by focusing research and development on glycoscience.